CN113621009A: beta-NMN chemical synthesis patent
A 2021 Chinese patent application from Chongqing Daxin Pharmaceutical and Peking University affiliates describes a chemical synthesis method for beta-NMN, an NAD precursor.
CN113621009A, a patent application titled "Chemical synthesis method of beta-nicotinamide mononucleotide (beta-NMN)," filed 25 June 2021. Applicants: Chongqing Daxin Pharmaceutical, Peking University Founder Group, and PKU Healthcare Industry Group. Inventors: 闫玉 and 张葵.
NMN is a precursor of NAD, used to increase NAD availability and support cellular energy metabolism. The claims and description reference phosphorylation, condensation, protecting groups, and purification. What the proposed method improves (yield, purity, cost, scalability) cannot be determined from the available patent text.
In the Eternal Search knowledge base, NMN appears in geroprotector reference articles (geroprotectors are substances hypothesized to slow aging) and is linked to the Brigham Boston XPrize project. The patent is also connected in the knowledge base to Nicotinamide Riboside (NR), a nicotinamide-based compound.
→ CN113621009A on Google Patents · NMN on Eternal Search
Sources
Chemical synthesis method of beta-nicotinamide mononucleotide
Most NMN connections in the graph point to clinical research, geroprotector lists, or aging timelines; this edge ties the term to a specific manufacturing patent from university-affiliated Chinese pharma, surfacing the supply-chain chemistry layer of the same compound.